Literature DB >> 24408296

[Narcolepsy].

G Mayer1.   

Abstract

Narcolepsy is a rare sleep disorder. The classical presentation includes the four symptoms excessive daytime sleepiness, cataplexy, sleep paralysis and hypnagogic hallucinations. As a model disease with all the transitions from awake to sleeping conditions, non-rapid eye movement (NREM) and rapid eye movement (REM), it plays an important role in neurology and sleep medicine. Patients with narcolepsy possess a reduced number of hypocretin-producing neurons in the hypothalamus and accordingly the hypocretin level in the cerebrospinal fluid is low. The neuropeptide hypocretin (orexin) has functions, such as the regulation of the sleep-wake cycle, the autonomous nerve system, motor system and metabolic processes. The delay in diagnosing narcolepsy is difficult to comprehend in modern medicine. The frequent association with other sleep-wake disorders may be responsible for the delay. Genomewide association studies have subsequently been able to prove that autoimmune mechanisms are responsible for the manifestation of narcolepsy with the HLA association being the most important for susceptibility and protection. Imaging studies have revealed neurodegenerative changes, making a multifactorial etiopathogenesis probable. The frequent occurrence of metabolic disorders has not yet been clarified. Early diagnosis of narcolepsy has the possibility to offer affected persons an adequate medication to lead an almost normal life and the future possibility to cure narcolepsy through immunomodulation therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24408296     DOI: 10.1007/s00115-013-3889-2

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  34 in total

1.  Increased body-mass index in patients with narcolepsy.

Authors:  A Schuld; J Hebebrand; F Geller; T Pollmächer
Journal:  Lancet       Date:  2000-04-08       Impact factor: 79.321

2.  Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis.

Authors:  Wynne Chen; Jed Black; Pamela Call; Emmanuel Mignot
Journal:  Ann Neurol       Date:  2005-09       Impact factor: 10.422

3.  Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment.

Authors:  Y Dauvilliers; B Abril; E Mas; F Michel; M Tafti
Journal:  Neurology       Date:  2009-10-20       Impact factor: 9.910

4.  DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe.

Authors:  Mehdi Tafti; Hyun Hor; Yves Dauvilliers; Gert J Lammers; Sebastiaan Overeem; Geert Mayer; Sirous Javidi; Alex Iranzo; Joan Santamaria; Rosa Peraita-Adrados; José L Vicario; Isabelle Arnulf; Giuseppe Plazzi; Sophie Bayard; Francesca Poli; Fabio Pizza; Peter Geisler; Aleksandra Wierzbicka; Claudio L Bassetti; Johannes Mathis; Michel Lecendreux; Claire E H M Donjacour; Astrid van der Heide; Raphaël Heinzer; José Haba-Rubio; Eva Feketeova; Birgit Högl; Birgit Frauscher; Antonio Benetó; Ramin Khatami; Francesca Cañellas; Corinne Pfister; Sabine Scholz; Michel Billiard; Christian R Baumann; Guadalupe Ercilla; Willem Verduijn; Frans H J Claas; Valérie Dubois; Jacek Nowak; Hans-Peter Eberhard; Sylvain Pradervand; Charlotte N Hor; Manuela Testi; Jean-Marie Tiercy; Zoltán Kutalik
Journal:  Sleep       Date:  2014-01-01       Impact factor: 5.849

5.  Acute effects of different glycemic index diets on serum motilin, orexin and neuropeptide Y concentrations in healthy individuals.

Authors:  Hui Wu; Fang-zhen Xia; Hui Xu; Hua-ling Zhai; Mei-fang Zhang; Hui-xin Zhang; Yan-xiang Li; Ying Li; Ting Gu; Li-Min Ma; Ying-li Lu
Journal:  Neuropeptides       Date:  2012-03-11       Impact factor: 3.286

6.  Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy.

Authors:  Hyun Hor; Zoltán Kutalik; Yves Dauvilliers; Armand Valsesia; Gert J Lammers; Claire E H M Donjacour; Alex Iranzo; Joan Santamaria; Rosa Peraita Adrados; José L Vicario; Sebastiaan Overeem; Isabelle Arnulf; Ioannis Theodorou; Poul Jennum; Stine Knudsen; Claudio Bassetti; Johannes Mathis; Michel Lecendreux; Geert Mayer; Peter Geisler; Antonio Benetó; Brice Petit; Corinne Pfister; Julie Vienne Bürki; Gérard Didelot; Michel Billiard; Guadalupe Ercilla; Willem Verduijn; Frans H J Claas; Peter Vollenweider; Peter Vollenwider; Gerard Waeber; Dawn M Waterworth; Vincent Mooser; Raphaël Heinzer; Jacques S Beckmann; Sven Bergmann; Mehdi Tafti
Journal:  Nat Genet       Date:  2010-08-15       Impact factor: 38.330

7.  Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients.

Authors:  Vesna Cvetkovic-Lopes; Laurence Bayer; Stéphane Dorsaz; Stéphanie Maret; Sylvain Pradervand; Yves Dauvilliers; Michel Lecendreux; Gert-Jan Lammers; Claire E H M Donjacour; Renaud A Du Pasquier; Corinne Pfister; Brice Petit; Hyun Hor; Michel Mühlethaler; Mehdi Tafti
Journal:  J Clin Invest       Date:  2010-02-15       Impact factor: 14.808

8.  Diet therapy for narcolepsy.

Authors:  A M Husain; W S Yancy; S T Carwile; P P Miller; E C Westman
Journal:  Neurology       Date:  2004-06-22       Impact factor: 9.910

Review 9.  Treatment of narcolepsy and other hypersomnias of central origin.

Authors:  Merrill S Wise; Donna L Arand; R Robert Auger; Stephen N Brooks; Nathaniel F Watson
Journal:  Sleep       Date:  2007-12       Impact factor: 5.849

10.  Non-dipping blood pressure profile in narcolepsy with cataplexy.

Authors:  Yves Dauvilliers; Isabelle Jaussent; Benjamin Krams; Sabine Scholz; Stéphane Lado; Patrick Levy; Jean Louis Pepin
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

View more
  2 in total

Review 1.  [Sleep disorders in neurological diseases].

Authors:  S Kotterba
Journal:  Nervenarzt       Date:  2015-06       Impact factor: 1.214

Review 2.  [Sleep and neurological diseases].

Authors:  G Mayer
Journal:  Nervenarzt       Date:  2016-06       Impact factor: 1.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.